admin To accelerate new vaccine development, US biotech and pharmaceutical company Moderna announced their collaboration with Korea University Medical Centre (KUMMC) in Seoul and Chosun University in Gwangju.
US Biotech made an announcement last Friday of the signing of contracts with the academic-industry cooperation foundations of KUMC and CU to research and develop medicines using the messenger ribonucleic acid (mRNA) platform.
Moderna wishes to launch its global public health program mRNA Access starting with South Korea.
Based on the reports on their announcements, the Cambridge, Massachusetts-based corporation said providing researchers with an mRNA platform can develop the development of new mRNA drugs.
“KUMC considers it highly significant to have the opportunity to research and develop the infinite potential of mRNA through this mRNA Access program concluded with Moderna,” said Kim Hak-Jun, president of KUMC’s Medical Research and Business Foundation.
“By joining Moderna’s mRNA Access program, we expect to contribute to the development of next-generation vaccines for the world through cooperation using our university’s excellent technology and Moderna, a global company specializing in mRNA medicine,” said Choe Han-Cheol, chairman of Chosun’s Industry-Academic Cooperation Foundation.
Magazine 
